UCSF

University of California San Francisco The celebrated fall of the *p*-value: Time for a new paradigm

Liz Whitlock, MD, MSc John Severinghaus Assistant Professor In Residence University of California, San Francisco Department of Anesthesia & Perioperative Care


MPOG Research Retreat October 12, 2018

No financial relationships to disclose

Funding: NIA GEMSSTAR R03AG059822, Foundation for Anesthesia Education & Research Jahnigan Career Development Award



Who's who in this talk's audience






It all begins with a "case"...

35yo F junior researcher submits a manuscript

- Major finding: CABG associated with equivalent of additional 4 months [95% CI -1 to 10] of cognitive aging at up to 2 years post-procedure
 - *p* = 0.12
 - "Population-level impact of surgery, if it exists, is likely to be subtle"



"Your borderline finding (P=0.12) and 95% CI cannot support this and so we remain uncertain."





The ASA's Statement on *p*-Values: Context, Process, and Purpose

In February 2014, George Cobb, Professor Emeritus of Mathematics and Statistics at Mount Holyoke College, posed these questions to an ASA discussion forum:

Q: Why do so many colleges and grad schools teach p = 0.05?

A: Because that's still what the scientific community and journal editors use.

Q: Why do so many people still use p = 0.05?

A: Because that's what they were taught in college or grad school.





Null hypothesis significance testing versus the estimation approach **"Beer**significance"

A new(ish?) way of thinking about significance

Null hypothesis significance testing

- Dichotomous: difference or not
 - A p value does not tell us what we want to know, and we so much want to know what we want to know that, out of desperation, we nevertheless believe that it does!"
- Frequently becomes "probability h₀ is true" – inverse probability fallacy

The estimation approach

- Also deals with...significance
- What do you want to know?
 - How much?
 - Does it really matter?
 - Should it change what you do?
- Study design (and bias)



Where did this tension come from? Historical context

Fisherian vs Gossetian statistics

- Randomized design
- Validity

"Theoretically plausible symmetric error distribution...around the mean result"

- Statistical significance
- "Student's" t-test

William Sealy Gosset (1876-1937) had a different definition of "validity"



"Beer-significance" Efficacy, value, strength, robustness



Ronald A. Fisher (1890-1962), deeply contemplating statistical significance


UCSF

Ziliak ST. The Validus Medicus and a new gold standard. Lancet 2010 Jul 31; 376(9738): 324-5 Ziliak ST & McCloskey DN. The Cult of Statistical Significance: How the Standard Error Costs Us Jobs, Justice, and Lives. Univ of Michigan Press, 2008 Fisher RA. Statistical methods for research workers. Oliver & Boyd (Edinburgh), 1925

Gosset, 1905, in a letter to Karl Pearson

"In such work as ours, the degree of certainty...must depend on the advantage to be gained by following the result of the experiment, compared with...the cost of the new method, and the cost of each experiment."





So, why don't we do it Gosset's way?

"[Significance testing at the 5% level has] raised economics, psychology, and medicine to the ranks of sciences." - Fisher, 1930



Where did p<.05 come from?

Overly simplistic, but close enough (see Cowles & Davis)

"Personally, the writer prefers to set a low standard of significance at the 5 per cent point, *and ignore entirely all results which fail to reach this level.*" Fisher RA, 1926

The New England Journal of Medicine

COMPARISON OF UPPER GASTROINTESTINAL TOXICITY OF ROFECOXIB AND NAPROXEN IN PATIENTS WITH RHEUMATOID ARTHRITIS

Claire Bombardier, M.D., Loren Laine, M.D., Alise Reicin, I Ruben Burgos-Vargas, M.D., Barry Davis, M.D., Ph.D., Richard Day Christopher J. Hawkey, M.D., Marc C. Hochberg, N AND THOMAS J. Schnitzer, M.D., Ph.D., for the

Annals of Internal Medicine

Also a bit overly simplistic, to be honest

Article

Gastrointestinal Tolerability and Effectiveness of Rofecoxib versus Naproxen in the Treatment of Osteoarthritis


A Randomized, Controlled Trial

Jeffrey R. Lisse, MD; Monica Perlman, MD, MPH; Gunnar Johansson, MD; James R. Shoemaker, DO; Joy Schechtman, DO; Carol S. Skalky, BA; Mary E. Dixon, BS; Adam B. Polis, MA; Arthur J. Mollen, DO; and Gregory P. Geba, MD, MPH, for the ADVANTAGE Study Group*

Fisher RA. The arrangement of field experiments. Journal of the Ministry of Agriculture 1926; 33:503-13. Cowles M & Davis C. On the origins of the .05 level of statistical significance. Am Psychol 1982 May; 37(5):553-8.




"Ignore entirely all results which fail to reach this level."



Bombardier C et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. NEJM 2000 Nov; 343:1520-1528. Lisse JR et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis. Ann Int Med 2003 Oct; 139(7):539-46. Ziliak & McCloskey. The Cult of Statistical Significance: Ch. 1

Even the Supreme Court has now weighed in





But we're WAY more sophisticated now.

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

SEPTEMBER 27, 2018

VOL. 379 NO. 13

Would you want your mom to wear a cardioverterdefibrillator vest?

Wearable Cardioverter–Defibrillator after Myocardial Infarction

Jeffrey E. Olgin, M.D., Mark J. Pletcher, M.D., M.P.H., Eric Vittinghoff, Ph.D., Je Rajesh Malik, M.D., Daniel P. Morin, M.D., M.P.H., Steven Zweibel, M.D., J Claude S. Elayi, M.D., Eugene H. Chung, M.D., Eric Rashba, M.D., Martin E Trisha F. Hue, Ph.D., M.P.H., Carol Maguire, R.N., Feng Lin, M.S., Joel A. Stephen Hulley, M.D., M.P.H., and Byron K. Lee, M.D., M.A.S., for the V

Of 2302 participants, 1524 were randomly assigned to the device group and 778 to the control group. Participants in the device group wore the device for a median of 18.0 hours per day (interquartile range, 3.8 to 22.7). Arrhythmic death occurred in 1.6% of the participants in the device group and in 2.4% of those in the control group (relative risk, 0.67; 95% confidence interval [CI], 0.37 to 1.21; P=0.18). Death from

CONCLUSIONS

Among patients with a recent myocardial infarction and an ejection fraction of 35% or less, the wearable cardioverter–defibrillator did not lead to a significantly lower rate of the primary outcome of arrhythmic death than control. (Funded by the Naux-

"Significantly": p<0.05 or 1/3 reduction?



How does this play out with very large samples?

"You can make the *p*-value as small as you can afford"

Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2011; all rights reserved. Advance Access publication 6 July 2011 International Journal of Epidemiology 2011;40:1292–1307 doi:10.1093/ije/dyr099

Risk factors and interventions with statistically significant tiny effects

George CM Siontis¹

2.6% probability that true OR is >1.03 0% probability that true OR is >1.05

ORIGINAL CONTRIBUTION

Risk Factors for Advanced Colonic Neoplasia and Hyperplastic Polyps in Asymptomatic Individuals

David A. Lieberman, MD Sheila Prindiville, MD, MPH David G. Weiss, PhD Walter Willett, MD, DrPH for the VA Cooperative Study Group 380 Context: Knowledge of risk factors for colorectal neoplasia could inform risk reduction strategies for asymptomatic individuals. Few studies have evaluated risk factors for advanced colorectal neoplasia in asymptomatic individuals, compared risk factors between persons with and without polyps, or included most purported risk factors in a multivariate analysis. **Objective** To determine risk factors associated with advanced colorectal neoplasia in a cohort of asymptomatic persons with complete colonoscopy.

	ysis of Risk	
Factors in Patien	vanced Neoplasia	
Factors	OR (95% Cl)*	
Family history of colon cancer	1.66 (1.16-2.35)	
Current smoking	1.85 (1.33-2.58)	
Current moderate to heavy alcohol consumption, per serving/wk	1.02 (1.01-1.03)	
Physical activity index,	0.94 (0.86-1.02)	

NEJM, JAMA, Lancet

RR 0.95-1.05

& p<0.05

Current cigarette smoking and contion of more than 7 drinks of alconot per week were strongly associated with increased risk, consistent with prior studies.⁴²⁻⁴⁶ Although the physiologic

sia. The risk associated with smoking and alcohol is now confirmed in a large multivariate analysis. Many prior stud-

plasia. Nevertheless, it is prudent to recommend that patients stop smoking, reduce alcohol intake, and exercise regularly as part of general preven-

Demidenko E. The p-value you can't buy. Am Stat 2016 Mar; 70(1):33-8.

Siontis GCM & Ioannidis JPA. Risk factors and interventions with statistically significant tiny effects. Int J Epidemiol 2011 Jul; 40:1292-1307. Lieberman et al. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. JAMA 2003 Dec; 290:2959-67.



I'd never do this. Never.

Research


JAMA Internal Medicine | Original Investigation

Association Between Persistent Pain and Memory Decline and Dementia in a Longitudinal Cohort of Elders

Elizabeth L. Whitlock, MD, MSc; L. Grisell Diaz-Ramirez, MS; M. Maria Glymour, ScD, MS; W. John Boscardin, PhD; Kenneth E. Covinsky, MD; Alexander K. Smith, MD, MPH


Perhaps a "tiny effect" transgression.


But I also did *something else* stemming from "significance = *significance*" that obstructs science...






Database research, odds ratios, and prediction








What's wrong with that?

that? Choose clinical issue & data Test a bunch of hypothesized predictors Generate prediction model

Prevent complications; save lives





What a	are we left with?	OR = 3.0 <u>D</u> <u>D</u> <u>D</u> <u>D</u> <u>D</u> <u>D</u> <u>D</u> <u>D</u> <u>D</u> <u>D</u>
Can't	Assume a decent OR will give you a useful prediction model or save lives	3 1 0 1 2 3
Can't	Assume a highly significant point estimate will be meaningful	Table 4. Multivariate Analysis of Risk 2.6% probability that true OR is >1.03 0% probability that true OR is >1.05 Control of the second secon
	Assume a non-significant point estimate isn't meaningful	Current smoking Current moderate to heavy alcohol consumption, per serving/wk Physical activity index, 0.94 (0.86-1.02)
		Would you want your
Materiality cannot be reduced to a	"Personally, the writer prefers to set a low standard of significance at the 5 per cent point, and ignore entirely all results which fail to reach this level." Fisher RA, 1926 Mar 2000: Nov 2000: Oct 2003: Sept 2004: Nov 2007: Merck NeJM paper Med paper withdrawn settlement	Modula you want your mom to wear a cardioverter- defibrillator vest? Of 2302 particip the control group, 18.0 hours per da ants in the device group wore the ants in the device group wore the cerquartile range, 3.8 to 22.7). Arrhyt 1.6% of the participants in the device group and in 2.4% of th (relative risk, 0.67; 95% confidence interval [CI], 0.37 to 1.2
bright-line rule.		UCCE

Now I feel frightened and powerless.

- Start to use our guts our judges of "beer significance" or more complex analyses translating effects into costs, lives, or function
- Demand effect sizes!
 - Change your language: "How much", not "Does it"

Things we can "feel" and understand

- Give as much attention to bias and study design as you do to point estimates and confidence intervals
 - Were the design and analysis good? Statistical significance becomes secondary.



Works cited

Historical literature

- Fisher RA. The arrangement of field experiments. Journal of the Ministry of Agriculture 1926; 33:503-13.
- Fisher RA. Statistical methods for research workers. Oliver & Boyd (Edinburgh), 1925

Recent primary literature

 Siontis GCM & Ioannidis JPA. Risk factors and interventions with statistically significant tiny effects. Int J Epidemiol 2011 Jul; 40:1292-1307.

Pepe MS et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epid 2004 159(9):882-90.

Analysis

• Ziliak ST. The Validus Medicus and a new gold standard. Lancet 2010 Jul 31; 376(9738); 221

Ziliak ST & McCloskey DN. The Cult of Statistical Significance: How the Standard Error Costs Us Jobs, Justice, and Lives. Univ of Michigan Press, 2008

- Wasserstein & Lazar, Am Stat 2010 10(2), 129-133, 2016
- Cowles M & Davis C. On the origins of the .05 level of statistical significance. Am Psychol 1982 May; 37(5):553-8.
- Ziliak & McCloskey. Lady Justice v. Cult of Statistical Significance. *In* Oxford Handbook on Professional Economic Ethics. Oxford UP, 2014.

Textbook for "estimation approach"

Cumming G & Calin-Jageman R. Introduction to the New Statistics. Routledge (New York, NY), 2017.

Not available, but presumably coming soon: <u>The American Statistician</u> special issue <u>Statistical Inference in the 21st</u> <u>Century: A World Beyond P<0.05</u>



